Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab in Spinal Cord Injury at Risk of HO
NCT07024407Phase 2Recruiting
- Sponsor
- āshibio
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of andecaliximab in heterotopic ossification (HO), sponsored by āshibio. Primary endpoints: Safety profile of andecaliximab at 13 weeks and Pharmacokinetic profile of andecaliximab at 9 weeks. Started May 2025; status: recruiting.
02
Drugs
andecaliximab
03
Conditions
heterotopic ossification (HO)
Beyond the preview
Go deeper on NCT07024407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024407.